Sanofi Files Consent Solicitation To Remove and Replace Medivation's Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Medivation (MDVN) Urges Holders to Reject Sanofi's Attempt to Replace Board
May 25, 2016 8:49 AM EDTMedivation, Inc. (NASDAQ: MDVN) today urged its stockholders to reject Sanofis attempt to replace the companys entire Board of Directors with hand-picked nominees through a proposed consent solicitation, which Medivation believes is a tactic for Sanofi to facilitate its substantially inadequate and opportunistically-timed proposal to acquire Medivation. Medivation expects to promptly file consent revocation materials with the U.S. Securities and Exchange Commission.
On April 29, 2016, the Medivation Board unanimously rejected Sanofis unsolicited, non-binding proposal to purchase Medivation for $52.50 per share in cash because it substantially undervalues the... More
